

# Correlation of Cystatin C with Atherogenic Indices in South Indian Obese Individuals

Rahul M. H<sup>1</sup>, Deepa K<sup>2\*</sup>, Varun Reddy<sup>3</sup>, Sudhir<sup>4</sup>, Shubha Jayaram<sup>5</sup>

<sup>1,3</sup>Intern, JSS Medical College, Mysore, <sup>2</sup>Assistant Professor,

<sup>5</sup>Associate Professor, Department of Biochemistry, Mysore Medical College & Research Institute, Mysore,

<sup>4</sup>Assistant Professor, Department of Community Medicine, Mandya Institute of Medical Sciences, Mandya

**\*Corresponding Author:**

E-mail: drdeepakrishna@yahoo.co.in

## ABSTRACT

**Introduction:** Obesity is the leading cause for cardiovascular disease in the world. Cystatin C is a novel marker of cardiovascular disease and atherogenic indices which is used as an index for cardiac risk stratification. The objective of the study was to estimate the Cystatin C levels in non-obese and obese individuals aged between 18-39 years and to compare the levels of Cystatin C among these individuals. The study was also done with an objective to know the association of Cystatin C with atherogenic indices.

**Methodology:** The subjects were selected from healthy volunteers of Mysore aged between 18-39 years of either sex. They were grouped into two groups based on their BMI. Each group had sample size of 60. Sample were collected in fasting state and analyzed for Total Cholesterol, Triglyceride, LDL-Cholesterol & HDL cholesterol by enzymatic method and Cystatin-C by immune-turbidimetric method using Randox auto-analyzer.

**Results and Interpretation:** The mean serum Cystatin C level in non obese group was  $0.7 \pm 0.03$  mg/L, and in Obese group  $1.15 \pm 0.09$  mg/L ( $p$  value  $< 0.001$ ). Serum Cystatin C showed a positive correlation with serum triglycerides ( $r=0.7$ ), Atherogenic index of plasma (AIP) ( $r=0.80$ ), TCHOL: HDL (Castelli's Risk Index I) ( $r=0.71$ ), HDL: LDL (Castelli's Risk Index II) ( $r=0.70$ ) and Atherogenic coefficient (AC)  $\{(Non\ HDLc)/HDLc\}$  ( $r=0.60$ ) respectively and negative correlation with serum HDL ( $r=-0.52$ ).

**Conclusion:** Several indices have been derived from lipid profiles to establish an index for predicting the risk of having coronary event. Cystatin C, was strongly correlated with the Atherogenic index of plasma (AIP), hence AIP can be used as a better index for screening the preclinical Cardiovascular event in obese individuals as estimation of Cystatin C is cost effective.

**Key Words:** Atherogenic Index of Plasma (AIP), Atherogenic coefficient (AC), Castelli's Risk Index (CRI), Cystatin C, Obesity.

Access this article online	
Quick Response Code:	Website: www.innovativepublication.com
	DOI: 10.5958/2394-6377.2015.00008.8

## INTRODUCTION

Cardiovascular disease is one of the commonest cause of mortality and coronary artery disease (CAD) accounts annually for 12 million deaths. There is a steady increase in the prevalence of CAD in the Indian subcontinent, due to rapid change in demography and lifestyle of people consequent to economic development<sup>1,2</sup>.

Obesity is the major cause for metabolic disorders and premature deaths in developing countries. It increases the risk of hypertension, dyslipidemia, diabetes mellitus and certain cancers<sup>3</sup>; however the underlying mechanism remains unclear. Recent evidences shows that body fat distribution during early adulthood is linked with increased metabolic disorder in later life<sup>4,5</sup>. Hence it necessitates the identification of possible biochemical predictors that can help in understanding atherogenicity. Cystatin C is a naturally occurring protease inhibitor and marker of cardiovascular disease. Cysteine protease cathepsin, is a pro-atherogenic factor which is produced

by adipose tissue and is increased in obese subjects<sup>6</sup>. Cysteine proteases are group of proteolytic enzymes which includes Cathepsin B, H, L, S and C that are involved in pathological processes such as inflammation, tumor invasion, breakdown of collagen and bone resorption<sup>7</sup>. The activities of Cysteine proteases are controlled by naturally occurring inhibitory proteins such as Cystatins and  $\alpha 2$  macroglobulin. These inhibitors functions to protect host tissues from destructive proteolysis. Cystatin C is a non glycosylated low molecular weight basic protein expressed in all nucleated cells<sup>8</sup>. Various indices have been used for the diagnosis of cardiovascular disease (CVD). Despite considerable advances, the evaluation of coronary heart disease (CHD) risk in asymptomatic obese individuals remains unclear. In the absence of an abnormal lipid profile the possibility of CAD cannot be ruled out. Hence it becomes important to find out different combinations of these lipid profile parameters which can be used to identify such high risk individuals. In this direction Atherogenic index of plasma (AIP) is emerging strongly as an index for cardiac risk stratification.

Atherogenic index of plasma (AIP) is a logarithmically transformed ratio of molar concentrations of triglycerides to HDL-cholesterol.  $AIP < 0.1$  is associated with low risk,  $0.1-0.24$  with medium risk, and  $> 0.24$  with high cardiovascular risk<sup>9</sup>. Thus, the present study was conducted with the objective of assessing the

significance of Cystatin C with the lipid ratios like Atherogenic Index of Plasma (AIP), Castelli Risk Index (CRI) and Atherogenic Coefficient (AC) in identification of risk for CAD in obese individuals.

## OBJECTIVES

1. To estimate the serum levels of Cystatin C in Obese individuals and compare it with non-obese.
2. To correlate the levels of Cystatin C with atherogenic indices.

## MATERIAL AND METHODS

The study design was a cross sectional study and subjects were selected from healthy volunteers of Mysore district aged between 18-39 years of either sex. The subjects were grouped into two group based on Body Mass Index, as per the Health Ministry of India guide lines<sup>10</sup>. Individuals with BMI of less than 23 kg/m<sup>2</sup> were grouped as normal, and those with BMI more than 25 kg/m<sup>2</sup> as obese. Each group had sample size of 60. The study was undertaken after ethical clearance from the Institutional Ethical Review Committee and written informed consent was taken from the all subjects.

**Exclusion Criteria:** Individuals with diabetes, hypertension, infections, chronic kidney disease and cancers were excluded from the studies. Data regarding age, sex, occupation, diet, physical activity, BMI, Blood pressure were collected using pre tested semi structured questionnaire.

Four ml of fasting venous sample was collected from all the individuals in a plain red Vacutainers under aseptic precautions. Serum glucose was estimated enzymatically by Glucose oxidase- Peroxidase method<sup>11</sup>, Total Cholesterol by cholesterol esterase and oxidase (CHOD-POP) method<sup>12</sup>, Direct HDL & Direct LDL Cholesterol by immune inhibition method<sup>13,14</sup> & VLDL was calculated by Friedwald's formula. Triglyceride by Glycerokinase and Glycerophosphate oxidase (GPO-PAP) methodology<sup>15</sup> and Cystatin C was estimated using immunoturbidimetric method<sup>16</sup>.

**Statistical Analysis:** The results were expressed as Mean  $\pm$  Standard deviation.  $p < 0.05$  was considered statistically significant. Statistical analysis was performed using Epi info software and to find the significance the test used was Student 't' test. To correlate the serum Cystatin C with atherogenic indices Pearson's correlation co-efficient was worked out.

## DISCUSSION

Epidemiological studies indicate that Cystatin C levels are elevated in renal dysfunction. The key finding in our study is that Cystatin C levels were significantly increased in obese group when compared to individuals with non obese. This observation suggests that higher BMI was associated with increase in Cystatin C levels in obese individuals which was independent of age & sex.

In support to our results, the study done by Nevio Taglieri et al<sup>17</sup> showed that Cystatin C was highly expressed in human adipose tissue, equivalently in subcutaneous and omental fat depots and increased levels of Cystatin C could be a part of regulatory mechanism in controlling the activities of Cathepsin proteases which is involved in Inflammations.

Lipid profile refers to some routinely done biochemical tests. It includes serum Triglycerides (TG), serum total cholesterol (TC) and its sub fractions like HDLc and LDLc. The role of deranged lipid profile in the progression of CAD is a well known fact and deranged LDLc levels are the primary target for treatment. Various indices had been derived from lipid profiles to establish an index for predicting the risk of having coronary event<sup>18,19</sup>.

In the present study serum Triglyceride (TG) was significantly increased in obese individuals with mean value of  $135.6 \pm 40.6$  mg/dl as compared with non obese  $115.6 \pm 20.1$  mg/dl and serum High Density Lipoproteins (HDL) levels was significantly lower in Obese with  $p < 0.05$ . These altered serum triglyceride (TG) and HDLc levels may be attributed to insulin resistance and increased HDL catabolism. Coronary Artery Disease (CAD) has been associated with alterations in lipid metabolism, which include hyper-triglyceridemia and significantly reduced HDLc, hence our study results was in agreement with Mudhaffar et al study<sup>20</sup>.

Interestingly the study showed higher AIP levels in obese individuals as compared with normal BMI with  $p < 0.001$ . AIP is a ratio calculated as  $\text{Log TG/HDLc}$ . In our observation AIP ratio was 0.26 in obese and -0.14 in non obese subjects. Hence AIP has diagnostic importance in predicting cardiovascular risk<sup>21</sup>.

Castelli's Risk Ratio (CRI) is based on three important lipid parameters i.e. Total Cholesterol (TC) LDLc and HDLc. CRI-I calculated as the ratio of TC/HDLc and CRI-II as LDLc/HDLc, and interestingly we found significantly higher ratio levels in obese with mean value of  $4.16 \pm 0.67$  &  $2.53 \pm 0.366$  respectively in comparison with non-obese. The study did not show any significant difference in TC and LDLc levels between the two study groups whereas, the ratio based on these parameters showed a significant difference between the two groups. This clearly suggests the relevance of ratios over individual lipid parameters especially in situations where the drug management might be affected. The Canadian working group had chosen the TC/HDLc ratio as a secondary goal of therapy considering it to be a more sensitive and specific index of cardiovascular risk than total cholesterol, particularly in individuals with  $\text{TG} > 300 \text{mg/dl}$ <sup>22,23</sup>. Few studies have also found an association of TC/HDLc ratio with coronary plaques formation<sup>24</sup>. Atherogenic Coefficient (AC), calculated as  $\text{Non-HDLc/HDLc}$  or  $\{(\text{TC-HDLc})/\text{HDLc}\}$  is a measure of cholesterol in LDLc, VLDLc, IDLc lipoprotein fractions with respect to HDLc. It reflects atherogenic potential of the entire spectrum of lipoprotein fractions.

Non HDLc is the second target of therapy after LDLc as per Adult treatment panel III guidelines especially in individuals with hyper-triglyceridemia<sup>25</sup>. In our study, the Atherogenic Coefficient (AC) was found to be significantly higher in obese individuals with  $p < 0.001$ . Moreover, it has been observed that obesity leads to rise in levels of small dense LDLc particles which are not measured routinely. Hence measurement of lipid ratios is equally important in indentifying the risk of Coronary artery disease in obese individuals which in turn helps in early diagnosis and effective treatment in order to postpone or control the disease process.

Since, atherogenic index of plasma was strongly correlated with the Cystatin C, hence AIP can be used as a better index for predicting the preclinical cardiovascular disease because of cost effectiveness in estimation of Cystatin C. Hence, AIP may be the diagnostic alternative for Cystatin C in predicting the early cardiovascular disease in obese individuals.

## RESULTS

**Table 1: Comparison of serum valves between the two study groups**

	Group 1	Group-2	P-values
N	55	55	-----
Age (years)	26.1±5.25	30.65±6.47	-----
BMI(Kg/m <sup>2</sup> )	20.7±1.6	29.6±3.63	0.0001*
Waist Circumference	81.6 ±11.3	95±12.6	0.0001*
Glucose(mg/dl)	80.5± 5.6	93.2± 6.5	0.0001*
Total Cholesterol(mg/dl)	132.2±9.44	139±19.3	0.0016
HDLCholesterol(mg/dl)	45.3±3.6	39.4±4.66	0.0002*
LDL Cholesterol(mg/dl)	99 ±8.8	102±14.30	0.0020
VLDL(mg/dl)	13.35±3.3	25.35±15.8	0.0023
Triglycerides(mg/dl)	115.6 ± 20.1	135.6 ± 40.6	0.0001*
AIP(log TG/HDL)	-0.14±0.06	0.26±0.10	0.0001*
T. Cholesterol/HDL(CRI-I)	2.83±0.3	4.16±0.67	0.0001*
HDL/LDL(CRI-II)	1.67±0.30	2.53±0.366	0.0001*
Non HDLc (TC-HDLc)	112.5±3.1	119.8±4.4	0.5
Cystatin C mg/L	0.70±0.033	1.15±0.09	0.0001*

N= number of subjects,  $p < 0.0001$  = highly significant.


Serum Cystatin C, Triglycerides & Glucose concentration were significantly increased in obese individuals when compared with non-obese control group. Serum Cystatin C levels in non-obese subjects was  $0.7 \pm 0.03$  mg/L, and in obese group  $1.15 \pm 0.09$  mg/L with  $p < 0.001$ . The mean AIP level (log TG/HDL) was  $-0.14 \pm 0.06$  and  $0.26 \pm 0.10$ , Castelli's Risk Index I was  $2.83 \pm 0.366$  &  $4.16 \pm 0.67$ , Castelli's Risk Index II was  $1.67 \pm 0.30$  &  $2.53 \pm 0.36$ , Atherogenic Co-efficient was  $2.93 \pm 0.16$  &  $4.28 \pm 0.37$  in non-obese and obese individuals respectively.

**Table 2: Shows the correlation between the Serum Cystatin C and Atherogenic indices**

Parameters	r-value	Correlation
Serum Glucose	0.61	Positive
AIP	0.8	Positive
HDL Cholesterol	-0.52	negative
Triglycerides	0.70	positive
TCHOL: HDL	0.71	Positive
HDL/LDL	0.70	Positive
NonHDLc/HDLc	0.60	Positive

In the study serum Cystatin C showed a positive correlation with Atherogenic index of plasma (AIP) ( $r=0.77$ ), Triglycerides ( $r=0.70$ ), TCHOL: HDL (Castelli's Risk Index I) ( $r=0.71$ ), HDL: LDL (Castelli's Risk Index II) ( $r=0.70$ ) respectively and Atherogenic coefficient (AC)  $\{(Non-HDLc)/HDLc\}$  ( $r=0.60$ ) and negative correlation with serum HDL ( $r=-0.52$ ).

#### Correlation between S. Cystatin and Log TG/HDL (AIP)



**Graph 1: Scatter plot showing relationship between S.Cystatin C and AIP. Correlation coefficient value shows that there is strong positive correlation between S. Cystatin and AIP. P value for 2 tailed tests is 0.032 which is less than 0.05. This shows that the correlation between S.Cystatin C and Log TG/HDL was statistically significant.**

#### REFERENCES

- World Health Organization, Preventing chronic disease: a vital investment, WHO global report, World Health Organization, Geneva, Switzerland, 2005.
- Dandona P, Aljada A, Chaudhuri A, Mohanty P, Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes & inflammation. *Circulation* 2005; 111:1448-1454.
- Nadia Naour, Soraya Fellahi, Jean- Francois et al. Potential contribution of adipose tissue to elevated Serum Cystatin C in human obesity. *Obesity* Dec-2009; 17:2121-2126.
- Libuse A, Bobek and Michael J, Levine. Cystatins- inhibitors of cysteine proteinases. *Critical reviews in oral biology & medicine*. 1992, 3(4); 307-332.
- Nevio Taglieri, Wolfgang Koenig & Juan Carlos kaski. Cystatin C and Cardiovascular risk, *Clinical Chemistry* 2009; 55; 11:1932- 1943.
- Tariq M, Rajab A. Comparative study for atherogenic index of plasma (AIP) in patients with type 1 diabetes mellitus, type 2 diabetes mellitus, beta thalassemia and hypothyroidism. *Int J Chem Res*. 2012; 2:1-9.
- India reworks obesity guidelines, BMI lowered. Available at [www.igovernment.in/site/India-reworks-obesity-guidelines-BMI-lowered/](http://www.igovernment.in/site/India-reworks-obesity-guidelines-BMI-lowered/) 11/26/2008. Accessed on 10/03/2015 at 13.50 hrs.
- Trinder P, Quantitative determination of glucose using GOD-PAP method, *Ann Clin Biochem* 1969; 6:24-27.
- Allain C.C, Poon LS, Chan CS et al 'Enzymatic determination of total serum cholesterol'. *Clin. Chem* 1974; 20,470.
- Rifai N, Warnick GR et al' Laboratory measurements of lipids, lipoproteins & Apolipoprotein. AACC Press; Washington DC, 1994; 335-336.
- Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of Low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. *Clin Chem* 1972; 18: 499-502.
- Schettler G, Nussel E, Jacob NJ 'Estimation of triglycerides by GPO-PAP method. *Arch Biochem Biophys*. 1960; 88: 250-255.
- Kyhse-Andersen J, Schmidt C, Nordin G et al, Serum Cystatin C, determined by a rapid, automated particles-enhanced turbidometric method is a better marker than serum Creatinine for glomerular filtration rate'. *Clin. Chem*. 1994;40:1921-26.
- Nadia Naour1, Soraya Fellahi, Jean-François Renucci, Christine Poitou, 'Potential Contribution of Adipose Tissue to Elevated Serum Cystatin C in Human Obesity' *Obesity* .2009; 17, 2121–2126.
- Parikh NI, Hwang SJ, Yang Q et al. Clinical correlates & heritability of Cystatin C. *American J Cardiol*. 2010; 102: 1194-98.
- Canello R, Henegar C, Viguier N *et al*. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. *Diabetes* 2013; 54: 2277–2286.
- Chapman HA, Riese RJ, Shi GP. Emerging roles for Cysteine proteases in human biology. *Annu Rev Physiol* 2012; 59:63–88.
- Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. *J Clin Invest* 2014;102:576–583
- Mudhaffar Sami Khazaal., Atherogenic Index of Plasma (AIP) As a Parameter in Predicting Cardiovascular Risk in Males Compared To the Conventional Dyslipidemic Indices. *Karbala J. Med* 2013; 6:1-6.
- Dobiasova M., Frohlich J., Sedova M., Cheung M.C., Brown B.G., Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography, *J Lipid Res*, 2014. 52:566–571.